zurück zur Startseite
Zentrale Tel.: 06221-560
Translational Lung Research Center Heidelberg

Mirjam Stahl, M.D.

Division of Pediatric Pulmonology & Allergy and Cystic Fibrosis Centre, Department of Pediatrics and Department of Translational Pulmonology, Translational Lung Research Centre Heidelberg (TLRC)

Heidelberg University Hospital
Im Neuenheimer Feld 430
69120 Heidelberg

Phone:+49 6221 56-5696
Opens window for sending emailE-Mail
Opens external link in new windowHomepage



Research Interests:

  • Phenotyping of early cystic fibrosis lung disease
  • Preventive and therapeutic approaches in newborns and infants with cystic fibrosis
  • Pulmonary function tests, especially multiple-breath washout (MBW)



Curriculum Vitae

2002-2004Medical School University of Rostock, Germany
2004-2008Medical School University of Freiburg, Germany
Since 2009Resident, University Medical Center for Children and Adolescents, Angelika Lautenschläger Hospital, Heidelberg University
Since 2009Clinical Research Fellow and Investigator in several investigator initiated trials in cystic fibrosis
Since 2014Principal Investigator of the Translational Lung Research Center Heidelberg (TLRC) and the German Center for Lung Research (DZL)



Honours & Awards

2010Travel award of the Cystic Fibrosis Foundation (North American Cystic Fibrosis Conference (NACFC), Baltimore/USA)
2010Travel award of the German Cystic Fibrosis Association (European Young Investigator Meeting (EYIM), Lille/France)
2012Travel award of the German Research Foundation (DFG Winter School Rare Diseases, Göttingen, Germany)
2013Travel award of the German Cystic Fibrosis Association (NACFC, Salt Lake City/USA)
2013Travel award of the German Cystic Fibrosis Association ((EYIM), Paris/France)
2013Poster Prize, 16th Annual German Cystic Fibrosis Meeting, Würzburg, Germany
2013Poster Prize, 36th Annual Meeting of GPP, Bremen, Germany
2015Young Scientist Research Grant, German Cystic Fibrosis Association (Mukoviszidose e.V.)



Memberships/Committee Assignments

2009Member of the German Society of Pediatrics and Adolescent Medicine (DGKJ)
2010Member of the German Society for pediatric Pulmonology (GPP)
2010Member of the German Society for pediatric allergology (GPA)
2011Member of the German German Cystic Fibrosis Association (Mukoviszidose e.V.)




  1. Characterization of early cystic fibrosis (CF) lung disease: Following up on early diagnosis based on the CF newborn screening, we are interested in the different aspects of early CF lung disease. Performing a longitudinal observational cohort study, our aim is to determine morphological changes by MRI and functional aspects by MBW. Furthermore, we are using the established, sensitive endpoints MRI and MBW for clinical interventional trials in newborns, infants and small children with CF, currently in the first preventive interventional trial on inhalation of hypertonic saline worldwide (ClinicalTrials.gov Identifier: NCT01619657).
  2. Use of MBW as pulmonary function test in infants and small children with different pulmonary diseases for which other tests are not available and as sensitive outcome parameter for multi-center interventional trials.



Simon Gräber, M.D.

Opens window for sending emailE-Mail



Study Coordinator

Stefan Fichtner

Opens window for sending emailE-Mail



Study Nurse

Cornelia Joachim

Opens window for sending emailE-Mail



Medical Documentation Assistent

Sylvia Seiler

Opens window for sending emailE-Mail

Selected Publications

  1. Stahl M, Joachim C, Blessing K, Hämmerling S, Sommerburg O, Latzin P, Mall MA. Multiple breath washout is feasible in the clinical setting and detects abnormal lung function in infants and young children with cystic fibrosis. Respiration 2014;87(5):357-63.

  2. Mall MA, Graeber SY, Stahl M, Zhou-Suckow Z. Early cystic fibrosis lung disease: Role of airway surface dehydration and lessons from preventive rehydration therapies in mice. Int J Biochem Cell Biol 2014;52:174-9.

  3. Wielpütz MO, Puderbach M, Kopp-Schneider A, Stahl M, Fritzsching E, Sommerburg O, Ley S, Sumkauskaite M, Biederer J, Kauczor HU, Eichinger M, Mall MA. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2014;189(8):956-65.

  4. Stahl M, Schupp J, Schmid M, Zissel G, Müller-Quernheim J, Prasse A. Collagen type I perpetuates pulmonary fibrosis via CD204 and M2 macrophage activation. PLoS One 2013;8(11):e81382.2013.

  5. Sommerburg O, Krulisova V, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmueller D, Happich M, Kulozik AE, Votava F, Balascakova M, Skalicka V, Stopsack M, Gahr M, Macek M Jr, Mall MA, Hoffmann GF. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central european populations. J Cyst Fibros 2013.

  6. Prasse A, Stahl M, Schulz G, Kayser G, Wang L, Ask K, Yalcintepe J, Kirschbaum A, Bargagli E, Zissel G, Kolb M, Müller-Quernheim J, Weiss JM, Renkl AC. Essential role of osteopontin in smoking-related interstitial lung diseases. Am J Pathol 2009;174(5):1683-91.

  7. Prasse A, Germann M, Pechkovsky DV, Markert A, Verres T, Stahl M, Melchers I, Luttmann W, Müller-Quernheim J, Zissel G. IL-10-producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients. J Allergy Clin Immunol 2007;119(2):464-71.
Select languageSelect language
Print Diese Seite per E-Mail weiterempfehlen